目的评估运动干预对中国高血压患者血压的影响,为我国高血压干预方案的进一步选择和优化提供参考依据。方法在中国知网(CNKI)、维普(VIP)、万方数据库和PubMed数据库、Cochrane图书馆、SpringerLink收集2012年1月1日至2016年12月31日国...目的评估运动干预对中国高血压患者血压的影响,为我国高血压干预方案的进一步选择和优化提供参考依据。方法在中国知网(CNKI)、维普(VIP)、万方数据库和PubMed数据库、Cochrane图书馆、SpringerLink收集2012年1月1日至2016年12月31日国内外公开发表的有关我国运动干预对高血压患者血压影响的随机对照试验,用Stata 12.0软件对纳入文献进行荟萃分析并进一步亚组分析,以收缩压和舒张压为主要效应指标。结果纳入22篇文献,干预组1105人,对照组1067人;荟萃分析结果表明,干预后运动干预组收缩压[加权均数差(WMD)=-10.71,95%CI-14.56^-6.86 mm Hg]和舒张压(WMD=-5.77 mm Hg,95%CI-8.26^-3.28)低于对照组(均P<0.01);不同运动干预时长、运动方式、运动频率及是否联合用药的亚组分析结果显示,运动干预组与对照组差异有统计学意义(均P<0.01);敏感性分析显示荟萃分析结果较为稳定可靠;Egger's线性回归法结果显示文章存在发表偏倚(P<0.05)。结论运动干预对高血压患者血压降低有一定的作用,不同方式运动干预达2个月对降低高血压患者血压有意义。展开更多
Background Polymer coating on coronary stents induces vascular inflammatory response, reduces re-endothelialization, and affects long-term outcome after percutaneous coronary intervention （PCI）. The SERY-1 registry ...Background Polymer coating on coronary stents induces vascular inflammatory response, reduces re-endothelialization, and affects long-term outcome after percutaneous coronary intervention （PCI）. The SERY-1 registry aimed to determine whether a novel polymer-free paclitaxel-eluting microporous Yinyi stent could improve 1-year outcome after index procedure in real-world clinical practice. Methods Clinical and angiographic data and follow-up outcome were collected in 1045 patients who underwent PCI with implantation of 〉1 Yinyi stents between June 2008 and August 2009 at 27 medical centers. The primary endpoint was the cumulative rate of composite major adverse cardiac events （MACE） and the secondary endpoint was the incidence of stent thrombosis at 1 year. Results Overall, 1376 lesions were treated successfully with 1713 Yinyi stents, and 1019 （98.7%） patients received dual antiplatelet therapy for at least 12 months. During 1-year follow-up, 8 patients （0.78%） had cardiac death, 6 （0.58%） suffered non-fatal myocardial infarction, and 46 （4.46%） underwent repeat PCI due to recurrence of angina, resulting in 1-year MACE-free survival of 94.09%. Stent thrombosis occurred in 10 （0.97%） patients, and the rate of Academic Research Consortium （ARC） definite or probable stent thrombosis was 0.78%. Conclusions Polymer-free paclitaxel-eluting microporous Yinyi stent is effective and safe for interventional treatment of coronary artery disease in real-world clinical practice, without recourse to carrier polymer. Potential long-term clinical advantages of this stent deserve further investigation.展开更多
文摘目的评估运动干预对中国高血压患者血压的影响,为我国高血压干预方案的进一步选择和优化提供参考依据。方法在中国知网(CNKI)、维普(VIP)、万方数据库和PubMed数据库、Cochrane图书馆、SpringerLink收集2012年1月1日至2016年12月31日国内外公开发表的有关我国运动干预对高血压患者血压影响的随机对照试验,用Stata 12.0软件对纳入文献进行荟萃分析并进一步亚组分析,以收缩压和舒张压为主要效应指标。结果纳入22篇文献,干预组1105人,对照组1067人;荟萃分析结果表明,干预后运动干预组收缩压[加权均数差(WMD)=-10.71,95%CI-14.56^-6.86 mm Hg]和舒张压(WMD=-5.77 mm Hg,95%CI-8.26^-3.28)低于对照组(均P<0.01);不同运动干预时长、运动方式、运动频率及是否联合用药的亚组分析结果显示,运动干预组与对照组差异有统计学意义(均P<0.01);敏感性分析显示荟萃分析结果较为稳定可靠;Egger's线性回归法结果显示文章存在发表偏倚(P<0.05)。结论运动干预对高血压患者血压降低有一定的作用,不同方式运动干预达2个月对降低高血压患者血压有意义。
文摘Background Polymer coating on coronary stents induces vascular inflammatory response, reduces re-endothelialization, and affects long-term outcome after percutaneous coronary intervention （PCI）. The SERY-1 registry aimed to determine whether a novel polymer-free paclitaxel-eluting microporous Yinyi stent could improve 1-year outcome after index procedure in real-world clinical practice. Methods Clinical and angiographic data and follow-up outcome were collected in 1045 patients who underwent PCI with implantation of 〉1 Yinyi stents between June 2008 and August 2009 at 27 medical centers. The primary endpoint was the cumulative rate of composite major adverse cardiac events （MACE） and the secondary endpoint was the incidence of stent thrombosis at 1 year. Results Overall, 1376 lesions were treated successfully with 1713 Yinyi stents, and 1019 （98.7%） patients received dual antiplatelet therapy for at least 12 months. During 1-year follow-up, 8 patients （0.78%） had cardiac death, 6 （0.58%） suffered non-fatal myocardial infarction, and 46 （4.46%） underwent repeat PCI due to recurrence of angina, resulting in 1-year MACE-free survival of 94.09%. Stent thrombosis occurred in 10 （0.97%） patients, and the rate of Academic Research Consortium （ARC） definite or probable stent thrombosis was 0.78%. Conclusions Polymer-free paclitaxel-eluting microporous Yinyi stent is effective and safe for interventional treatment of coronary artery disease in real-world clinical practice, without recourse to carrier polymer. Potential long-term clinical advantages of this stent deserve further investigation.
